Axonis Therapeutics, a Boston, MA-based biotechnology company focused on the development of novel neuromedicines, raised $115M in Series A funding.
The round was led by Cormorant Asset Management and venBio Partners with participation from Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, Lumira Ventures and Solasta Ventures.
The company intends to use the funds to advance its lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain.
Led by Joanna Stanicka, Ph.D., CEO and President, Axonis Therapeutics is a neuro-focused biotechnology company developing medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Université Laval.
In conjunction with the financing, Axonis also announced the appointments of Donald Manning, M.D., Ph.D., as Chief Medical Officer and Jeff Imbaro, M.B.A., as Chief Operating Officer.
FinSMEs
30/10/2024